The SARS-CoV-2 pandemic transformed life as we know it. Around the world, shops, schools, banks and borders closed en masse.
Even the pharmaceutical/drug development industry – which held the key to successfully navigating through the pandemic – struggled to continue operations as usual. A significant number of clinical trials were abandoned outright for safety and logistical reasons, while those that did take place faced innumerable challenges.
This white paper examines this topic in detail. It outlines the hurdles that clinical trials had to overcome during SARS-CoV-2 and identifies key lessons we can apply if there is another pandemic in the future.